Related Experiment Video
Updated: Feb 13, 2026

A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells
Published on: June 16, 2022
Cisplatin binds to pre-miR-200b and impairs its processing to mature microRNA
Abstract:
Cisplatin is an important anticancer drug with a complex mode of action, a variety of possible targets, and numerous resistance mechanisms. While genomic DNA has traditionally been considered to be its most critical anticancer target, several lines of evidence suggest that various RNAs and other biomolecules may play a role in its anticancer mode of action. In this report we demonstrate that cisplatin modifies pre-miR-200b, impairs its processing to mature miRNA, and decreases miR-200b expression in ovarian cancer cells. Considering the role of miR-200b in epithelial-to-mesenchymal transition and cancer chemosensitivity, cisplatin-induced modification of pre-miR-200b and subsequent deregulation of mature miR-200b may, depending on cell context, limit anticancer activity of this important anticancer drug. More gener- ally, precursor miRNAs may be important targets of cisplatin and play a role in this drug's anticancer activity or modulate cell responses to this drug.
Insights
Cisplatin modifies precursor microRNA-200b (pre-miR-200b) in ovarian cancer cells, reducing mature miR-200b levels. This interaction may impact the drug
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cisplatin is a widely used chemotherapy agent.
- Its primary target is genomic DNA, but other biomolecules may also be involved.
- MicroRNAs (miRNAs) play roles in gene regulation and cancer progression.
Purpose of the Study:
- To investigate the effect of cisplatin on precursor microRNA-200b (pre-miR-200b) in ovarian cancer cells.
- To determine if cisplatin affects the processing of pre-miR-200b into mature miR-200b.
- To explore the implications of these findings for cisplatin's anticancer activity.
Main Methods:
- Ovarian cancer cells were treated with cisplatin.
- Levels of pre-miR-200b and mature miR-200b were measured.
- The processing of pre-miR-200b was assessed.
Main Results:
- Cisplatin treatment led to the modification of pre-miR-200b.
- The processing of pre-miR-200b into mature miR-200b was impaired.
- Mature miR-200b expression was decreased in ovarian cancer cells.
Conclusions:
- Cisplatin targets pre-miR-200b, affecting mature miR-200b levels.
- This interaction may influence cisplatin's efficacy in ovarian cancer.
- Precursor miRNAs could be novel targets for anticancer drugs.
Related Concept Videos
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
MicroRNAs
MicroRNAs
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Pre-mRNA Processing: Modification of pre-mRNA Ends
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
Pre-mRNA Processing: RNA Splicing

